Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.24 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.27 |
| trials ClinicalTrials.gov | 43 Parkinson's trials, 3 stopped | 0.94 |
| literature PubMed | 239 Parkinson's papers of 56,266 | 0.28 |
| pathways Reactome | 2 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 1760
Sealed predictions
- COPE in dopamine neurons, braak-0.13 (p 0.735) → -0.82 (p 0.007)receipt 1768
Swarm cases
receipt 1768: COPE in dopamine neurons, braak
- power
- full sample -0.41 (p 0.091, n 18), 95% CI -0.74 to +0.07. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.44 (p 0.064, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.42 (p 0.086, n 18). could be the mix.
- skeptic
- leave-one-out range -0.50 to -0.34, sign flips 0; without severely affected donors -0.41 (p 0.091, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for COPE in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts